{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:37:13Z","timestamp":1771007833474,"version":"3.50.1"},"reference-count":41,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,9,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Cisplatin kills tumor cells through DNA cross linking. Alterations in the function of DNA repair genes may affect DNA repair proficiency and influence cancer patients' response to cisplatin. We studied whether single nucleotide polymorphisms (SNPs) of DNA repair genes predict the response to cisplatin or prognosis in patients with squamous cell carcinoma of the head and neck (SCCHN). <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> A polymerase chain reaction\u2013restriction fragment length polymorphism (RFLP) approach was used to determine the frequency of the SNPs: XPD-Asp312Asn, XPD-Lys751Gln, ERCC1-C8092A, and XRCC1-Arg399Gln in DNA from peripheral lymphocytes of 103 stage IV SCCHN patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> The frequencies of the distinct genotypes were, respectively, for the homozygous common allele, heterozygous and homozygous polymorphic variant: 53%, 40%, and 7% for ERCC1; 50%, 42%, and 8% for XPD-312; 35%, 57%, and 8% for XPD751; and 35%, 51%, and 13% for XRCC1. Patients with only common alleles at all the SNPs tested had a median overall survival of 5.1 months (range, 4.3 to 6.0 months) as compared with not reached for patients with at least one polymorphic variant (P &lt; .001). Estimates from Cox's multivariate analysis suggest that the accumulation of each polymorphic variant decreases the probability of dying by a factor of 2.1 (P &lt; .001; the presence of seven polymorphic variants confers a 175-fold protection). The accumulation of polymorphic variants increases by 2.94-fold the probability of achieving a complete response to treatment (P = .041). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Using a multivariate model, the presence of polymorphic variants in DNA-repair genes are powerful prognosis factors and response to cisplatin predictors among SCCHN patients. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2006.05.8768","type":"journal-article","created":{"date-parts":[[2006,8,9]],"date-time":"2006-08-09T03:38:54Z","timestamp":1155094734000},"page":"4333-4339","source":"Crossref","is-referenced-by-count":108,"title":["DNA-Repair Gene Polymorphisms Predict Favorable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy"],"prefix":"10.1200","volume":"24","author":[{"given":"Miguel","family":"Quintela-Fandino","sequence":"first","affiliation":[{"name":"Medical Oncology Department. University Hospital 12 de Octubre. Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Hitt","sequence":"additional","affiliation":[{"name":"Medical Oncology Department. University Hospital 12 de Octubre. Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro P.","family":"Medina","sequence":"additional","affiliation":[{"name":"Lung Cancer Group. Molecular Pathology Programme. Spanish National Cancer Centre (CNIO), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soledad","family":"Gamarra","sequence":"additional","affiliation":[{"name":"Molecular Biology Division, Hematology Department. University Hospital 12 de Octubre, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Manso","sequence":"additional","affiliation":[{"name":"Medical Oncology Department. University Hospital 12 de Octubre. Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernan","family":"Cortes-Funes","sequence":"additional","affiliation":[{"name":"Medical Oncology Department. University Hospital 12 de Octubre. Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Sanchez-Cespedes","sequence":"additional","affiliation":[{"name":"Lung Cancer Group. Molecular Pathology Programme. Spanish National Cancer Centre (CNIO), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra001375"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.9.583"},{"key":"R4","unstructured":"Adelstein DJ, Adams GL, Li Y, et al: A phase III comparison of standard radiation therapy (RT) versus RT plus concurrent cisplatin (DDP) versus split-course RT plus concurrent DDP and 5-fluorouracil (5FU) in patients with unresectable squamous cell head and neck cancer (SCHNC): An Intergroup study. Prog Proc Am Soc Clin Oncol 19:411a,2000,  (abstr 1624)"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1318"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806183382503"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.4.265"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106133242402"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1512"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf172"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.13.890"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2715"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.006"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.026"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200207000-00007"},{"key":"R16","unstructured":"Cmelak A, Murphy BA, Burkey B, et al: Induction chemotherapy (IC) followed by concurrent chemoradiation (CCR) for organ preservation (OP) in locally advanced squamous head and neck cancer (SHNC): Results of a Phase II trial. Proc Am Soc Clin Oncol 22:501,2003,  (abstr 2016)"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.1990"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf268"},{"key":"R19","unstructured":"Benasso M, Numico G, Rosso R, et al: Chemotherapy for relapsed head and neck cancer: Paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients\u2014A dose-finding study. Semin Oncol 24:46,1997-50,  (suppl)"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200004000-00005"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh145"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.02.019"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.057"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Vermorken JB, Remenar E, Van Herpen C, et al: Standard cisplatin\/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). J Clin Oncol 23:488,2004,  (suppl; abstr 5508)","DOI":"10.1200\/jco.2004.22.90140.5508"},{"key":"R25","unstructured":"Johnson SW, Stevenson JP, O'Dwyer PJ: Cisplatin and its analogues, in DeVita VT, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology . Philadelphia, PA, Lippincott Williams and Wilkins, pp 380,2001-382"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199308000-00011"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.14.1091"},{"key":"R28","unstructured":"Shen MR, Jones IM, Mohrenweiser H: Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58:604,1998-608,"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.4.551"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.5.965"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601061"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.2594"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0247"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh319"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.11.019"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R37","unstructured":"Chen P, Wiencke J, Aldape K, et al: Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9:843,2000-847,"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/22.4.593"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-05-0162"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1021\/bi00026a031"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Rosell R, Taron M, Ariza A, et al: Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 31:20,2004-27,","DOI":"10.1053\/j.seminoncol.2003.12.011"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90544-N"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.05.8768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:22:33Z","timestamp":1653513753000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.05.8768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,10]]},"references-count":41,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2006,9,10]]}},"alternative-id":["10.1200\/JCO.2006.05.8768"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.05.8768","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,10]]}}}